SLC5A2 and type 2 diabetes mellitus: Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), represents a novel therapeutic agent for patients with type 2 diabetes by inhibiting renal reabsorption of glucose.